The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

Figure 4

Overall survival for 307 patients with newly diagnosed symptomatic multiple myeloma according to the ISS stages I, II, and III, who were treated with thalidomide-based treatment as first-line therapy.